Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net (loss) income	$ (6,271)	$ (7,464)	$ 5,140
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	7,039	7,056	3,546
Impairment loss	1,200	0	0
Share based compensation, net	(6,586)	6,869	6,617
Deferred income taxes	5,249	292	(1,630)
Bad debt expense	365	324	214
(Increase) decrease in operating assets and increase (decrease) in liabilities:
Accounts receivable	601	(1,742)	(41)
Inventories	12,351	(6,417)	13,432
Prepaid income taxes	(111)	675	(182)
Prepaid expenses and other current assets	995	(185)	147
Operating lease right-of-use assets, net	466	788	0
Accounts payable	(13,460)	6,102	(2,292)
Sales tax payable	(145)	(1,101)	1,956
Accrued expenses and other current liabilities	3,921	276	896
Operating lease liabilities	(458)	(766)	0
Deferred revenue	(518)	(390)	0
Income taxes payable	80	0	0
Net cash provided by operating activities	4,718	4,317	27,803
Cash flows from investing activities:
Purchase of minority interest investment in Vetster	0	(300)	(5,000)
Acquisition of PetCareRx, net of cash acquired	0	(35,859)	0
Purchases of property and equipment	(5,113)	(4,511)	(5,260)
Net cash used in investing activities	(5,113)	(40,670)	(10,260)
Cash flows from financing activities:
Dividends paid	(181)	(12,437)	(24,537)
Net cash used in financing activities	(181)	(12,437)	(24,537)
Net decrease in cash and cash equivalents	(576)	(48,790)	(6,994)
Cash and cash equivalents, at beginning of fiscal year	55,296	104,086	111,080
Cash and cash equivalents, at end of fiscal year	54,720	55,296	104,086
Supplemental disclosure of cash flow information:
Cash paid for income taxes	525	130	4,312
Dividends payable in accrued expenses	26	1,466	1,262
Non-cash investing activity for property and equipment additions	$ 2,170	$ 0	$ 0